In 2017 the Familial Amyloid Polyneuropathy (FAP) patient in the United States was found to be 2,588 while Italy and France had 612 and 512 FAP patients respectively.
With a growth rate of 10.2% Hereditary Transthyretin Amyloidosis (hATTR) has the highest diagnosed prevalence in the United States while Japan has the lowest number which is expected to grow at a CAGR of 9.9% over the forecast period.
The market size of Hereditary Transthyretin Amyloidosis (hATTR) in the 7MM was USD 306.9 Million in 2017.
The key players in the Hereditary Transthyretin Amyloidosis (hATTR) market includes Alnylam Pharmaceuticals, Eidos Therapeutics, Ionis Pharmaceuticals and many others.
For more details on hrrt market visit: https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market